- £592.13m
- £621.80m
- $929.10m
- 76
- 48
- 96
- 88
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 960 | 626 | 522 | 726 | 929 |
Cost of Revenue | |||||
Gross Profit | 266 | 125 | 101 | 171 | 228 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 913 | 846 | 601 | 724 | 868 |
Operating Profit | 46.8 | -220 | -79.7 | 2 | 61 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 45.6 | -223 | -85.5 | -2.4 | 50 |
Provision for Income Taxes | |||||
Net Income After Taxes | 41.4 | -238 | -89.7 | -3.7 | 119 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 39.7 | -235 | -85.8 | -4.6 | 117 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 39.7 | -235 | -85.8 | -4.6 | 117 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.389 | -0.431 | -0.301 | 0.032 | 0.201 |
Dividends per Share |